News and talk of GLP-1 drugs are everywhere these days—from their smash success in treating Type 2 diabetes and obesity to their astronomical pricing, drug shortages, compounding disputes, and what sometimes seems like an ever-growing list of other conditions the drugs could potentially treat. There are new headlines every day. However, while the drugs have […]
Others have already stopped sales, like Eden, which has created a special landing page declaring compounded tirzepatide to be “banned nationwide!” Ro, one of the most prominent telehealth companies in the space, has also stopped offering the product. “We are working to ensure our patients have the best options available to them to preserve continuity […]
The end of the tirzepatide shortage has created a fraught moment for many patients taking the compounded version of the drug. As WIRED recently reported, many of these patients are concerned that they will not be able to afford or access the name-brand versions of their medication. While Eli Lilly recently introduced a new, cheaper […]
Despite the boom in popularity of expensive GLP-1 drugs to treat weight loss, fewer than one in … [+] five large employers are covering such prescriptions, a new KFF analysis shows. In this photo is Ozempic, a GLP-1 for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. (Photo […]
